Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The Dr Trust Bestest Compressor Nebulizer is a highly efficient and reliable device for home use. It features a powerful ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

This growth is driven by the increasing shift toward home-based healthcare and the rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma.

A psychoeducational intervention for extrapulmonary manifestations of severe asthma was found feasible and rated as ...